Medication transitions are critical periods in patient care, particularly for those with complex medical regimens or chronic conditions. Effective rehabilitation during these transitions, coupled with robust therapeutic self-management strategies, can mitigate risks associated with polypharmacy, adverse drug events, and non-adherence. This review synthesizes current evidence and guideline-based recommendations, emphasizing the integration of rehabilitation principles and self-management education to optimize therapeutic outcomes and patient safety during medication transitions.
Transitions in medication regimens whether due to changes in clinical status, evolving guidelines, or the introduction of new therapies represent a vulnerable juncture for patients. Inadequate management during these periods can result in adverse drug reactions, treatment failures, or rehospitalizations. Rehabilitation approaches, traditionally applied to physical recovery, are increasingly recognized for their value in supporting medication transitions and fostering patient-centered therapeutic self-management. This article reviews the epidemiology, mechanisms, clinical features, and management strategies associated with medication transition rehabilitation, offering evidence-based guidance for healthcare professionals.
Medication transitions are common in both inpatient and outpatient settings, affecting an estimated 30-70% of patients during hospital admission or discharge. Polypharmacy prevalence among older adults exceeds 40%, amplifying the risks of inappropriate medication use and adverse events during transitions. Studies indicate that up to 60% of medication errors occur during transitions of care, with significant consequences for morbidity, mortality, and healthcare utilization. Chronic disease populations, such as those with heart failure, diabetes, or psychiatric disorders, are disproportionately impacted, underscoring the need for targeted rehabilitation strategies.
The pathophysiological basis for medication transition complications involves pharmacokinetic and pharmacodynamic changes, drug-drug and drug-disease interactions, and alterations in organ function (e.g., hepatic or renal impairment). Abrupt discontinuation or initiation of therapies can unmask withdrawal syndromes or precipitate loss of disease control. Neurocognitive and physical impairments further compound the risk, particularly in older or multimorbid patients. Rehabilitation interventions can address these vulnerabilities by systematically assessing and supporting physiological adaptation during transitions.
Key risk factors include advanced age, polypharmacy, multiple comorbidities, cognitive impairment, low health literacy, lack of social support, and transitions across multiple care settings. High-risk medications (e.g., anticoagulants, antidiabetics, psychotropics) are particularly prone to error during switching. Inadequate communication between healthcare providers, insufficient medication reconciliation processes, and poor patient engagement exacerbate these risks. Identifying and mitigating these factors is central to a successful rehabilitation and self-management program.
Clinical manifestations of poor medication transition management range from mild symptoms (dizziness, confusion, gastrointestinal upset) to severe complications such as organ dysfunction, falls, hospital readmissions, and mortality. Patients may present with signs of withdrawal, toxicity, or exacerbation of underlying conditions. Behavioral changes, reduced adherence, and loss of functional independence are also observed. Early recognition of these features is essential for timely intervention.
Diagnosis relies on comprehensive medication reconciliation, clinical assessment, and monitoring for signs of adverse drug events or withdrawal syndromes. Tools such as the Medication Appropriateness Index, STOPP/START criteria, and electronic health record alerts facilitate identification of high-risk transitions. Patient-reported outcomes and functional assessments provide additional insight into the impact of medication changes on daily living and self-management capacity.
Optimal management involves a multidisciplinary approach integrating clinical pharmacology, rehabilitation medicine, pharmacy, nursing, and patient education. Key strategies include individualized medication review, structured transition protocols, and close follow-up. Rehabilitation interventions may encompass cognitive training, functional mobility support, and adherence-enhancing technologies. Therapeutic self-management is fostered through patient-centered education, motivational interviewing, and shared decision-making, enabling individuals to recognize signs of adverse events, adhere to complex regimens, and actively participate in their care. Early involvement of caregivers and community resources further supports sustained outcomes.
Recent advances include the development of digital health tools for medication tracking, artificial intelligence-driven risk stratification, and tele-rehabilitation models that provide ongoing support during transitions. Pharmacogenomic testing is emerging as a tool to personalize medication regimens and minimize adverse events. Mobile applications and remote monitoring devices facilitate real-time adherence tracking and symptom reporting, bridging the gap between clinic visits. The integration of behavioral health support and peer coaching into rehabilitation programs has shown promise in improving self-management, particularly in vulnerable populations.
Current guidelines from organizations such as the American Geriatrics Society, Institute for Healthcare Improvement, and WHO emphasize the importance of systematic medication reconciliation, patient and caregiver education, and structured handoff communication during transitions. Rehabilitation should be tailored to patient-specific needs, with ongoing assessment of cognitive, functional, and psychosocial status. Guidelines recommend engaging patients in shared decision-making and leveraging multidisciplinary teams to optimize medication safety and therapeutic outcomes. Regular follow-up and re-assessment are essential to ensure sustained self-management and early detection of complications.
Rehabilitation for medication transition and therapeutic self-management is an evolving field that bridges clinical pharmacology, rehabilitation medicine, and patient education. By adopting a multidisciplinary, patient-centered approach, healthcare professionals can reduce adverse outcomes, enhance medication adherence, and empower patients to actively manage their health during vulnerable transition periods. Ongoing research, technological innovation, and adherence to evidence-based guidelines will further refine these strategies, ultimately improving the quality and safety of medication transitions across healthcare settings.
1.
Study: Rapamycin slows the progression of cancer by reducing aging and concentrating on precancerous cells.
2.
Can Alternating Venetoclax Regimens Improve AML Outcomes?
3.
Cancer detection recovered following pandemic disruptions
4.
COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment
5.
Research identifies nearly 200 potential breast carcinogens in food packaging materials
1.
A Clinical Review of Novel Therapeutics for Rare Cancers in the Genomics Era
2.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
3.
Unlocking the Mystery of Elliptocytes: Exploring the Unusual Shape of Red Blood Cells
4.
From Autoimmune Disorders to COVID-19: How Plasmapheresis Is Revolutionizing Modern Medicine
5.
Uncovering the Causes of Thrombocytosis: A Journey to Improved Health
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Chemotherapy: What to Expect
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
3.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
4.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation